The grant, from the National Institute of Allergy and Infectious Diseases under the National Institutes of Health (NIH), will help Micronics determine whether its rapid nucleic acid test to diagnose HIV is comparable in both sensitivity and specificity to the only FDA licensed diagnostic nucleic acid test in use currently.
The project is expected to demonstrate the detection of HIV in a droplet of blood applied to a small disposable cassette that contains all of the required reagents and controls to perform a nucleic acid assay.
Karen Hedine, CEO and president of Micronics, said: “The overall objective of the NIH grant is to determine whether our test can provide the same kind of information as the current nucleic acid test in use today.”